Efficacy of Oral Propranolol on the Treatment of Retinopathy of Prematurity

Mina Hosseini; Manijeh Mostafa Gharebaghi; Masood Bagheri; Sadollah Yeganehdoost; Amir Eftekhari Milani; Mohamad Reza Niyousha

doi:10.34172/cjmb.2022.10

E-ISSN : 2148-9696

Crescent Journal of
Medical and Biological Sciences

Main Page Aim and Scope Instructions to Authors Editorial Policies Editorial Board Authorship Agreement Form Open Access and Copyright

Jan 2022, Vol 9, Issue 1

CURRENT ISSUE ARCHIVE AHEAD OF PRINT / ACCEPTED ARTICLE MOST VIEWED ARTICLES NEWS RELATED LINKS

Advanced Search

For Author's & Reviewer's

Committee on Publication
Ethics (COPE) Flowchart

Recommendations for the Conduct

World Association of Medical Editors(WAME)

EQUATOR Resources : Reviewers

Poll

How do you find the scientific quality of the published articles on our web site?

Very good

Good

Fair

Bad

Very bad

Original Article
Efficacy of Oral Propranolol on the Treatment of Retinopathy of Prematurity
Mina Hosseini¹, Manijeh Mostafa Gharebaghi¹, Masood Bagheri^2,3, Sadollah Yeganehdoost¹, Amir Eftekhari Milani³, Mohamad Reza Niyousha³
¹Alzahra Hospital, Children Medical Research and Training Hospital, Tabriz University of Medical Sciences, Tabriz, Iran ²Department of Ophthalmology, Imam Khomeini Eye Center, Kermanshah University of Medical Sciences, Kermanshah, Iran ³Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran
CJMB 2022; 9: 056-062 DOI: 10.34172/cjmb.2022.10 Viewed : 2528 times Downloaded : 2874 times. Keywords : Propranolol, Avastin, Laser therapy, Retinopathy of prematurity
Full Text(PDF) \| Related Articles
Abstract

Objectives: Due to recent advances in caring for premature neonates, premature retinopathy has become an important cause of preventable blindness and ocular disabilities. Therefore, more attention is paying to its diagnostic-therapeutic methods. Thus, the current trial assessed the efficacy of oral propranolol on the treatment of retinopathy of prematurity (ROP) in neonates. Materials and Methods: In the current trial, 58 neonates with ROP were included and the efficacy of oral propranolol (0.5 mg/kg every 8 hours) was compared with the control group. Results: In the intervention group, the stage of ROP was almost the same as the control group while 31.1% of neonates in the control group were progressed to stage 3. On the other hand, it was only 6.9% (P = 0.009) in the intervention group. In patients receiving propranolol, only 2 cases required invasive therapeutic interventions whereas 9 patients required such interventions in the control group (P = 0.009). The ROP improvement rate was significantly higher in the intervention group. In the control group, the overall progression to higher stages was about 48.3% while it was 13.8% for the intervention group. The mean age of neonates at the time of retinal artery completion was 91.40 ± 22.16 and 128.08 ± 79.89 days for the control and intervention groups, respectively (P = 0.136). Conclusions: The results of this study showed that adding oral propranolol to standard therapy can reduce the rate of ROP progression to higher stages in preterm neonates with low birth weight, and the need for invasive treatments.